查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011699

慢性阻塞性肺病（COPD）治療市場：依產品類型、藥物類別、給藥途徑及通路分類－2026-2032年全球市場預測

Chronic Obstructive Pulmonary Disease Treatment Market by Product Type, Drug Class, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，慢性阻塞性肺病(COPD) 治療市場價值將達到 899.5 億美元，到 2026 年將成長至 966.4 億美元，到 2032 年將達到 1535 億美元，複合年成長率為 7.93%。

主要市場統計數據
基準年 2025 899.5億美元
預計年份：2026年 966.4億美元
預測年份 2032 1535億美元
複合年成長率 (%) 7.93%

重點突出、結合實際情況的介紹，概述了正在重塑全球 COPD 治療路徑的臨床進展、醫療設備創新和商業性因素。

慢性阻塞性肺病（COPD）仍然是發病率和醫療資源消耗的主要原因之一，臨床、商業和政策領域的相關人員必須適應治療方法和給藥方法創新步伐的加快。長效支氣管擴張劑、標靶抗發炎策略和吸入裝置設計的進步正在改變人們對症狀控制和急性惡化預防的預期。同時，報銷模式的轉變以及對病人依從性和品質指標的日益重視，正在重新定義支付方和醫療服務提供者眼中的價值。

對臨床、技術和政策領域正在發生的整合變化進行了清晰的概述，這些變化正在重新定義 COPD 管理的治療策略和商業模式。

慢性阻塞性肺病（COPD）的治療現況正經歷著變革，這主要得益於臨床實務、技術和政策的進步。臨床上，治療模式正從單一療法轉向聯合治療，即結合長效支氣管擴張劑和抗發炎藥物，以應對患者的不同表現型。隨著臨床治療的不斷發展，標靶藥物和支持療法也在日趨成熟，旨在有效控制症狀並降低急性惡化風險。

對不斷變化的進口關稅措施如何重塑整個 COPD 治療市場的供應鏈、籌資策略和臨床可用性進行全面分析。

影響藥品原料、成品吸入器和契約製造原料的關稅措施的推出和加強，為供應鏈負責人和銷售團隊帶來了重大考量。關稅相關的成本壓力往往表現為原料和零件價格上漲、物流和海關手續日益複雜，以及與供應商關係的重組。實際上，製造商正在加快採取措施，透過探索替代採購管道、與供應商談判簽訂長期價格合約以及擴大國內或本地產能來降低關稅波動帶來的風險。

從綜合細分觀點，重點闡述產品類型、藥物類別、給藥途徑和分銷管道如何相互作用，從而決定 COPD 治療中的臨床應用和商業策略。

基於細分市場的洞察揭示了治療需求、臨床應用和商業管道如何在產品類型、藥物類別、給藥途徑和通路之間相互作用。就產品類型而言，抗生素、皮質類固醇、長效支氣管擴張劑、磷酸二酯酶-4抑制劑和短效支氣管擴張劑之間的差異分別代表著不同的臨床作用：抗生素通常間歇性用於感染疾病控制；皮質類固醇以各種劑型發揮抗發炎作用；長效支氣管擴張劑作為維持治療症狀；這些功能差異會影響處方集納入、病患教育重點和生產週期。

一份詳細的區域評估報告，闡述了醫療保健系統、法律規範和供應鏈能力如何影響世界各地的 COPD 治療方法。

區域趨勢對治療重點、監管路徑和供應鏈決策產生了意義深遠且獨特的影響。在美洲，醫療保健系統通常優先考慮基於價值的支付模式和能夠支持全面護理和藥物依從性計劃的大規模綜合醫療保健網路。在此背景下，製藥公司需要證明其產品在真實臨床環境中的有效性，並與醫療保健系統合作開展試點項目，整合數位化藥物依從性工具和病患教育，以減少病情加重和再入院。

決定 COPD 治療領域企業績效和合作的策略考量因素，包括競爭定位、夥伴關係模式和創新重點。

慢性阻塞性肺病（COPD）領域的企業競爭格局主要受治療方法差異化、醫療設備創新、策略夥伴關係和業務永續營運等因素驅動。創新生物製藥公司持續專注於差異化聯合治療和標靶抗發炎策略，以期在不同表現型亞群中展現臨床療效。醫療設備製造商則致力於研發符合人體工學且具備數位化連接功能的產品，以減少誤用並收集用藥依從性數據，從而提升其對支付方和醫療服務提供者的價值提案。

為專注於產品差異化、供應鏈韌性、數位整合和支付方合作的高階主管提供實用建議，以在 COPD 治療領域建立永續的競爭優勢。

產業領導企業可以透過整合符合支付方期望和患者需求的營運和臨床優先事項來提升自身競爭力。首先，將醫療設備設計改進與實證醫學方案結合，可確保新劑型得到結果數據的支持，從而證明其能夠減少誤用並提高患者依從性。將產品創新與強大的上市後監測和真實世界數據 (RWE) 的產生相結合，可提供檢驗價值提案、支持擴大適應症和醫療保險報銷談判所需的資訊。

透過文獻整合、專家訪談、實際應用分析和供應鏈映射等嚴謹且多方面的研究途徑，獲得了切實可行的見解。

本分析所依據的研究採用了一種多方面方法，旨在整合臨床、商業和供應鏈訊號。透過對同儕審查文獻和監管指導文件的系統性回顧，我們確立了臨床背景，並為治療方法和醫療設備的檢驗提供了基礎。此外，我們也對臨床專業人員、醫院藥劑師、醫療設備工程師和供應鏈管理人員進行了定性訪談，以了解他們對用藥依從性挑戰、醫療設備易用性和採購壓力等方面的實際觀點。

一項權威的綜合分析強調了整合臨床創新、醫療設備的易用性和供應鏈韌性對於加快 COPD 患者的治療效果和商業性成功至關重要。

總之，慢性阻塞性肺病（COPD）治療生態系統正處於一個轉折點，臨床創新、醫療設備進步、供應鏈策略和支付方期望在此交匯融合，重新定義了價值主張。整合實證治療方法方案、提升醫療設備易用性以及提供數位化用藥依從性支持的相關人員，能夠更好地實現病患療效。同時，商業性韌性——包括採購多元化、確保區域製造地以及協同需求預測——對於商業成功至關重要，能夠保障供應穩定，並降低可能導致成本增加或供應中斷的關稅和物流風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：慢性阻塞性肺病（COPD）治療市場：依產品類型分類

  • 抗生素
  • 皮質類固醇
  • 長效支氣管擴張劑
  • 磷酸二酯酶-4抑制劑
  • 短效支氣管擴張劑

第9章：慢性阻塞性肺病（COPD）治療市場：依藥物類別分類

  • 抗膽鹼能藥物
  • BETA-激動劑
  • 皮質類固醇
  • 甲基黃嘌呤類類藥物

第10章：慢性阻塞性肺病（COPD）治療市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
  • 靜脈注射
  • 口服

第11章：慢性阻塞性肺病（COPD）治療市集：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：慢性阻塞性肺病（COPD）治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：慢性阻塞性肺病（COPD）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章慢性阻塞性肺病（COPD）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國慢性阻塞性肺病（COPD）治療市場

第16章 中國慢性阻塞性肺病（COPD）治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-43676CF42C41

The Chronic Obstructive Pulmonary Disease Treatment Market was valued at USD 89.95 billion in 2025 and is projected to grow to USD 96.64 billion in 2026, with a CAGR of 7.93%, reaching USD 153.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 89.95 billion
Estimated Year [2026] USD 96.64 billion
Forecast Year [2032] USD 153.50 billion
CAGR (%) 7.93%

A focused and contextual introduction that frames the clinical advances, device innovation, and commercial forces reshaping COPD treatment pathways worldwide

Chronic Obstructive Pulmonary Disease remains a leading cause of morbidity and healthcare utilization, and stakeholders across clinical, commercial, and policy domains must adapt to an accelerating pace of therapeutic and delivery innovation. Advances in long acting bronchodilators, targeted anti-inflammatory strategies, and inhalation device design are changing expectations for symptom control and exacerbation prevention. At the same time, shifts in reimbursement models and heightened attention to patient adherence and quality metrics are redefining value for payers and providers.

Consequently, clinicians are balancing established guideline-based therapy with growing interest in personalized treatment algorithms informed by biomarkers such as blood eosinophil counts. Device selection and inhalation technique have emerged as critical determinants of real-world effectiveness, prompting an emphasis on patient education and the integration of digital adherence tools. Pharmaceutical manufacturers and device companies are responding by prioritizing combination regimens, streamlined dosing formats, and improved user ergonomics that reduce misuse and enhance persistence.

Furthermore, the commercial landscape is shaped by evolving supply chains, regulatory scrutiny over manufacturing quality, and new entrants in generics and biosimilars that alter competitive dynamics. Taken together, these forces create both complexity and opportunity: stakeholders that align clinical evidence, device usability, and resilient supply strategies will be better positioned to deliver sustainable improvements in patient outcomes.

An incisive overview of the converging clinical, technological, and policy shifts that are redefining therapeutic strategies and commercial models in COPD care

The COPD treatment landscape is undergoing transformative shifts driven by converging clinical, technological, and policy developments. Clinically, the paradigm has moved beyond monotherapy toward combination regimens that integrate long acting bronchodilators with anti-inflammatory agents to target heterogeneous patient phenotypes. This clinical evolution is accompanied by the maturation of targeted pharmacologic classes and adjunctive approaches that address both symptom control and exacerbation risk.

Technologically, inhalation device innovation is accelerating. Dry powder inhalers, metered dose inhalers, and nebulizer platforms are receiving incremental redesigns to improve dose delivery and reduce user error, while digital adherence sensors and connected platforms are enabling new models of remote monitoring and patient engagement. These technologies are starting to influence prescribing behavior by providing objective adherence data that can be used in clinical decision making.

On the commercial and regulatory front, stakeholders face greater scrutiny of manufacturing quality and supply chain robustness, prompting strategies such as supplier diversification and regional manufacturing capacity expansion. Payer dynamics are shifting toward outcomes-oriented contracting and value demonstration, which favors therapies and delivery systems that show consistent real-world performance. Collectively, these shifts are redefining how therapies are developed, positioned, and delivered, and they create a competitive environment in which clinical differentiation and operational resilience are both essential for long term success.

A comprehensive analysis of how evolving import tariff measures are reshaping supply chains, procurement strategies, and clinical availability across COPD therapeutics

The introduction and escalation of tariff measures affecting pharmaceutical components, finished inhalation devices, and contract manufacturing inputs have created a material set of considerations for supply chain planners and commercial teams. Tariff-induced cost pressures tend to manifest through higher raw material and component prices, increased logistics and customs complexity, and reconfiguration of supplier relationships. In practice, manufacturers have been evaluating alternative sourcing geographies, negotiating longer term supplier contracts to lock in pricing, and accelerating onshore or nearshore capacity to mitigate exposure to tariff volatility.

Beyond procurement costs, tariffs can influence clinical availability through extended lead times and inventory management changes. Health systems and pharmacies may proactively increase stockholding of critical finished inhalers and parenteral therapies to buffer against supply interruptions, which in turn affects working capital and distribution planning. Regulatory agencies and trade bodies often respond with temporary waivers, expedited inspections, or tariff exemptions for essential medicines, but these mechanisms are not uniformly applied and can be slow to implement.

In addition, tariff dynamics tend to catalyze strategic behaviors such as consolidation of purchasing across hospital systems, expanded use of contract manufacturing organizations with diversified footprints, and increased investment in formulation or device adaptations that reduce reliance on import-sensitive components. For payers and providers, the cumulative effect is heightened attention to cost containment and continuity of care, while manufacturers must balance price pressure with continued investment in clinical differentiation and device innovation.

An integrative segmentation perspective highlighting how product types, drug classes, administration routes, and distribution channels jointly determine clinical use and commercial strategy in COPD care

Segmentation-driven insights illuminate how therapeutic demand, clinical utilization, and commercial channels interact across product types, drug classes, routes of administration, and distribution pathways. When considering product type, distinctions among antibiotics, corticosteroids, long acting bronchodilators, phosphodiesterase four inhibitors, and short acting bronchodilators reveal differentiated clinical roles: antibiotics are often episodic for infection management, corticosteroids serve as anti-inflammatory backbones in various delivery forms, long acting bronchodilators provide maintenance symptom control, phosphodiesterase four inhibitors target specific exacerbation-prone phenotypes, and short acting bronchodilators remain central to rescue therapy. These functional differences influence formulary placement, patient education priorities, and manufacturing cadence.

Examining drug class underscores the therapeutic mechanisms at play: anticholinergics and beta agonists are primary classes for bronchodilation, corticosteroids provide anti-inflammatory benefit in appropriate patients, and methylxanthines occupy a niche role where oral therapy is indicated. Route of administration further stratifies performance and adoption. Inhalation remains the preferred modality for targeted pulmonary delivery and is subdivided into dry powder inhalers, metered dose inhalers, and nebulizers, each with distinct patient suitability, device complexity, and adherence considerations. Intravenous formulations are primarily relevant in acute care settings, while oral agents offer systemic options for select patient groups.

Distribution channel analysis reveals differentiated access and service models. Hospital pharmacies support inpatient and acute care needs with tighter clinical oversight, online pharmacies present convenience and subscription models that can improve adherence but require robust authentication and cold chain considerations where applicable, and retail pharmacies provide broad community access and counseling touchpoints that are essential for long term therapy maintenance. Integrating these segmentation lenses enables targeted commercial strategies and clinical pathways that better match product characteristics to patient needs and operational realities.

A nuanced regional assessment describing how healthcare systems, regulatory frameworks, and supply chain capabilities shape COPD treatment approaches across global regions

Regional dynamics shape therapeutic priorities, regulatory pathways, and supply chain decisions in meaningful and distinctive ways. In the Americas, healthcare systems commonly emphasize value-based payment models and large integrated delivery networks that can support bundled care and adherence programs. This context encourages manufacturers to demonstrate real-world effectiveness and to partner with health systems on pilots that integrate digital adherence tools and patient education to reduce exacerbations and hospital readmissions.

In Europe, Middle East & Africa, the regulatory and reimbursement environment is heterogeneous, with well established national HTA frameworks in some markets and evolving access infrastructures in others. Stakeholders operating in this region must navigate country specific formularies and procurement mechanisms while also accounting for diverse device preferences and variable cold chain or distribution infrastructures in certain jurisdictions. Partnerships with local distributors and investments in regulatory expertise are common approaches to achieve consistent market entry and post launch support.

In the Asia-Pacific region, the landscape is marked by rapid uptake of generics, significant manufacturing capacity for APIs and finished dosage forms, and growing patient demand for accessible therapies. Policymakers and payers are increasingly focused on improving affordability while maintaining quality standards, which incentivizes contract manufacturing partnerships and regional supply hubs. Across all regions, digital health adoption, telemedicine, and remote monitoring are emerging enablers of improved COPD management, though the pace and nature of adoption vary by healthcare system maturity and reimbursement models.

A strategic examination of competitive positioning, partnership models, and innovation priorities that define company performance and collaboration in COPD therapeutics

Competitive dynamics among companies in the COPD space are driven by therapeutic differentiation, device innovation, strategic partnerships, and operational resilience. Innovator biopharmaceutical companies continue to focus on differentiated combination therapies and targeted anti-inflammatory approaches that can demonstrate clinical benefit across phenotypic subgroups. Device manufacturers are investing in human factors engineering and digital connectivity features to reduce misuse and to capture adherence data that support value arguments with payers and providers.

Generic and specialty pharmaceutical firms are enhancing their portfolios through lifecycle management and by leveraging contract manufacturing to scale production efficiently. Contract development and manufacturing organizations are expanding capacity in regions with favorable regulatory frameworks to support rapid commercial supply and to reduce geopolitical exposure. Meanwhile, diagnostics and digital health providers are creating complementary offerings-such as remote monitoring platforms and inhaler sensors-that enrich therapeutic value propositions and enable new care pathways focused on prevention of exacerbations.

Mergers, acquisitions, and strategic alliances are common tactics to accelerate time to market for novel formulations and device integrations. Across the competitive landscape, success increasingly hinges on the ability to align clinical evidence generation with pragmatic delivery solutions and to demonstrate consistent real-world outcomes that resonate with payers, providers, and patients.

Actionable recommendations for executives focusing on product differentiation, supply chain resilience, digital integration, and payer alignment to drive sustained competitive advantage in COPD care

Industry leaders can strengthen their competitive posture by pursuing a cohesive set of operational and clinical priorities that align with payer expectations and patient needs. First, integrating device design improvements with evidence generation plans ensures that new delivery formats are supported by outcomes data demonstrating reduced misuse and improved adherence. Complementing product innovation with robust post market surveillance and real-world evidence generation helps to validate value propositions and to inform label expansions and reimbursement negotiations.

Second, companies should prioritize supply chain resilience by diversifying supplier bases, qualifying dual sources for critical APIs and components, and evaluating regional manufacturing partnerships to reduce exposure to tariff and logistical volatility. Strategic inventory policies and collaborative forecasting with major purchasers can also reduce stockout risk while limiting excess inventory costs. Third, investing in digital health adjuncts-such as connected inhaler technologies and remote monitoring platforms-creates differentiation and supports clinical workflows that reduce acute utilization.

Finally, proactive payer engagement and outcome based contracting pilots can accelerate access while aligning incentives around reduced exacerbations and hospitalizations. By combining these levers-product and device innovation, supply chain diversification, digital integration, and value-based commercial models-industry leaders can achieve sustainable differentiation and better patient outcomes.

A rigorous, multi method research approach combining literature synthesis, expert interviews, real world utilization analysis, and supply chain mapping to inform actionable insights

The research underpinning this analysis used a multi method approach designed to triangulate clinical, commercial, and supply chain signals. A structured review of peer reviewed literature and regulatory guidance documents established the clinical context and informed classification of therapeutic and device modalities. This was augmented by qualitative interviews with clinical specialists, hospital pharmacy directors, device engineers, and supply chain managers to capture frontline perspectives on adherence challenges, device usability, and procurement pressures.

In addition, proprietary analysis of anonymized claims and utilization datasets provided insights into treatment patterns and care settings, while inspection of public regulatory filings and device approvals clarified recent innovation trajectories. Supply chain mapping exercises identified common points of vulnerability for APIs and device components, and scenario planning workshops informed the assessment of tariff impacts and mitigation strategies. Throughout, methodological rigor was maintained by cross checking primary data sources against independent clinical guidelines and regulatory outcomes to ensure consistency and to highlight areas of divergence that warrant further investigation.

A conclusive synthesis emphasizing the imperative to integrate clinical innovation, device usability, and supply chain resilience to advance COPD patient outcomes and commercial success

In conclusion, the COPD treatment ecosystem is at an inflection point where clinical innovation, device evolution, supply chain strategy, and payer expectations intersect to redefine value delivery. Stakeholders that integrate evidence based therapy selection with device usability improvements and digital adherence supports are positioned to achieve better patient outcomes. Concurrently, commercial success requires operational resilience-diversified sourcing, regional manufacturing options, and collaborative forecasting-to mitigate tariff and logistical risks that could disrupt availability and increase costs.

Going forward, alignment across the product lifecycle-from R&D through post market surveillance-and close collaboration with payers and providers will be essential. Decision makers should view the current environment as an opportunity to consolidate learnings from pilot programs, scale interventions that demonstrably reduce exacerbations, and invest in technologies that support sustained adherence. With thoughtful execution, organizations can translate emerging science and device capabilities into meaningful improvements in COPD care while safeguarding supply continuity and competitive positioning.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Obstructive Pulmonary Disease Treatment Market, by Product Type

  • 8.1. Antibiotics
  • 8.2. Corticosteroids
  • 8.3. Long Acting Bronchodilators
  • 8.4. Phosphodiesterase Four Inhibitors
  • 8.5. Short Acting Bronchodilators

9. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Class

  • 9.1. Anticholinergics
  • 9.2. Beta Agonists
  • 9.3. Corticosteroids
  • 9.4. Methylxanthines

10. Chronic Obstructive Pulmonary Disease Treatment Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Dry Powder Inhaler
    • 10.1.2. Metered Dose Inhaler
    • 10.1.3. Nebulizer
  • 10.2. Intravenous
  • 10.3. Oral

11. Chronic Obstructive Pulmonary Disease Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Chronic Obstructive Pulmonary Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Chronic Obstructive Pulmonary Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Chronic Obstructive Pulmonary Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Chronic Obstructive Pulmonary Disease Treatment Market

16. China Chronic Obstructive Pulmonary Disease Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AstraZeneca PLC
  • 17.6. Aurobindo Pharma Ltd.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Chiesi Farmaceutici S.p.A.
  • 17.9. Cipla Ltd.
  • 17.10. GlaxoSmithKline plc
  • 17.11. Glenmark Pharmaceuticals Ltd.
  • 17.12. Hikma Pharmaceuticals PLC
  • 17.13. Lupin Limited
  • 17.14. Merck & Co., Inc.
  • 17.15. Mylan N.V.
  • 17.16. Novartis AG
  • 17.17. Orion Corporation
  • 17.18. Pfizer Inc.
  • 17.19. Sun Pharmaceutical Industries Ltd.
  • 17.20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LONG ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE FOUR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SHORT ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)